1. Combined intravenous and oral mesna in outpatients treated with ifosfamide

   • Marshall P. Goren
   • Linda M. McKenna
   • Thomas L. Goodman

   ORIGINAL ARTICLE Pages: 371 - 375

2. Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion

   • L. D. Nord
   • R. L. Stolfi
   • D. S. Martin

   ORIGINAL ARTICLE Pages: 376 - 384

3. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells

   • Laurent Poulain
   • François Sichel
   • Jean-Yves Le Talaër

   ORIGINAL ARTICLE Pages: 385 - 390

4. Urinary stability of carboxycyclophosphamide and carboxyifosfamide, two major metabolites of the anticancer drugs cyclophosphamide and ifosfamide

   • Claire Joqueviel
   • Véronique Gilard
   • Ulf Niemeyer

   ORIGINAL ARTICLE Pages: 391 - 399

5. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines

   • E. H. Herman
   • J. Zhang
   • V. J. Ferrans

   ORIGINAL ARTICLE Pages: 400 - 408

6. Characterization of the mechanisms of busulfan resistance in a human glioblastoma multiforme xenograft

   • C. Bradley Hare
   • Gertrude B. Elion
   • Henry S. Friedman

   ORIGINAL ARTICLE Pages: 409 - 414

7. Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer

   • Vincent A. Miller
   • James R. Rigas
   • Mark G. Kris

   ORIGINAL ARTICLE Pages: 415 - 418

8. Pharmacokinetics of doxorubicin and epirubicin in mice during chlorpromazine-induced hypothermia

   • L. Lundgren-Eriksson
   • A. Carlsson
   • R. Hultborn

   ORIGINAL ARTICLE Pages: 419 - 424

9. A novel quinoline derivative, MS-209, overcomes drug resistance of human lung cancer cells expressing the multidrug resistance-associated protein (MRP) gene

   • Fumihiko Narasaki
   • Mikio Oka
   • Shigeru Kohno

   ORIGINAL ARTICLE Pages: 425 - 432

10. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines

    • Yuko Hoki
    • Akira Fujimori
    • Yves Pommier

    ORIGINAL ARTICLE Pages: 433 - 438

11. Zeniplatin in advanced malignant melanoma and renal cancer: phase II studies with unexpected nephrotoxicity

    • Steinar Aamdal
    • Uta Bruntsch
    • Stan B. Kaye

    CLINICAL TRIAL REPORT Pages: 439 - 443

12. Digitonin enhances the efficacy of carboplatin in liver tumour after intra-arterial administration

    • P. G. Lindnér
    • Dennis Heath
    • Larsolof R. Hafström

    SHORT COMMUNICATION Pages: 444 - 448

13. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients

    • Toshiaki Takahashi
    • Y. Fujiwara
    • Michio Yamakido

    SHORT COMMUNICATION Pages: 449 - 452

14. An N-myristoylated protein kinase C-α pseudosubstrate peptide that functions as a multidrug resistance reversal agent in human breast cancer cells is not a P-glycoprotein substrate

    • Philip J. Bergman
    • Karen R. Gravitt
    • C. A. O’Brian

    SHORT COMMUNICATION Pages: 453 - 456